Top news of the week: 27.07.2021.
Healthcare
#Hutchmed #Orpathys better positioned to gain from #AstraZeneca commercial experience in #China, says #GlobalData
https://t.co/X1wUcaufwj
#NonSmallCellLungCancer
Open23 Jul 2021 Hutchmed Orpathys better positioned to gain from AstraZeneca commercial experience in China, says GlobalData
Hutchmed (China) Limited’s Orpathys (savolitinib) is now launched in China for patients with lung cancer and MET exon 14 skipping alterations that have progressed following...
RT @OncimmuneECDT: "We are delighted to be partnering with such a prestigious organisation as @DanaFarber on the use of multiple CPI assets in this important oncology trial and leveraging the power of our #autoantibody #biomarker profiling technology.” @Tech_Trender
https://t.co/mYKb57E98i
OpenOncimmune Holdings PLC
Oncimmune Holdings plc ("Oncimmune" or the "Company") Agreement signed with major cancer center to profile patients in immuno-oncology trial Oncimmune Holdings plc (AIM: ONC.L), …
This week, the Joint Committee on Vaccination and Immunisation (JCVI) advised that children and people under 18 who are at increased risk of severe COVID-19 should be offered the Pfizer-BioNTech vaccine. Read more on our blog post. https://t.co/wqL6Xie3JW
Open
COVID-19 vaccine and cancer – latest updates
Recently, news of a COVID-19 vaccine has dominated headlines. We've summarised all the information that is out there, with rolling updates, in our new vaccine blog post.
@roelgrif @keshy2020 Janssen is a one-dose vaccine, the table shows the mRNA, 2-dose vaccines data.
Janssen efficacy (J&J page):
https://t.co/FkCIUYOuZM
@CDCgov:
https://t.co/7PUWTWu0K8
So far no decision was made on a need (or lack thereof) for a second dose of Janssen or any booster shot for it.
Open
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Delta Variant
Demonstrated strong neutralizing antibody activity against the Delta (B.1.617.2) variant Persistent immune responses through at least eight months